SAN DIEGO, Aug. 29, 2018 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members
of its senior management team will participate in the upcoming
investor conferences:
- Wells Fargo Securities Global Healthcare Conference –
Presenting on Wednesday, September 5
at 2:25 p.m. EDT in Boston
- Citi Annual Biotech Conference – Hosting investor meetings on
Thursday, September 6 in Boston
- Morgan Stanley Annual Global Healthcare Conference – Presenting
on Friday, September 14 at
10:30 a.m. EDT in New York City
A live audio webcast of the presentations will be available
under the investor relations section of Arena's website at
www.arenapharm.com. A replay of the presentation will be available
for 30 days following the event.
About Arena Pharmaceuticals
Arena Pharmaceuticals is
focused on delivering novel, transformational medicines with
optimized pharmacology and pharmacokinetics to patients globally.
Arena's proprietary pipeline includes multiple potentially first-
or best-in-class programs with broad clinical utility. The most
advanced investigational clinical programs are ralinepag (APD811),
in a Phase 3 program for pulmonary arterial hypertension (PAH), and
etrasimod (APD334), expected to commence a Phase 3 program for
ulcerative colitis (UC) and a program in Crohn's disease (CD), and
which has potential utility for a broad range of immune and
inflammatory conditions. Arena is also evaluating olorinab (APD371)
in a Phase 2 study for the treatment of visceral pain associated
with Crohn's disease, as well as other drug candidates in earlier
research and development stages.
In addition, Arena has several collaborations including Everest
Medicines Limited (ralinepag and etrasimod in Greater China and select Asian countries),
Axovant Sciences GmbH (nelotanserin - Phase 2), Boehringer
Ingelheim International GmbH (undisclosed target - preclinical),
Outpost Medicine, LLC (undisclosed target – preclinical), and Eisai
Co., Ltd. and Eisai Inc. (BELVIQ® - marketed
product).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. These forward-looking statements may be
accompanied by words such as "will," "focused on," "potentially,"
"expected," "potential," or words of similar meaning, or they may
be identified by the fact that they do not relate strictly to
historical or current facts. Such forward-looking statements
include, without limitation, statements about the upcoming
presentations and Arena's focus, goals, strategy, clinical programs
and collaborations. For such statements, Arena claims the
protection of the Private Securities Litigation Reform Act of 1995.
Actual events or results may differ materially from Arena's
expectations. Factors that could cause actual results to differ
materially from the forward-looking statements include that
clinical programs may not proceed at the time or in the manner
expected or at all, as well as those factors disclosed in Arena's
filings with the Securities and Exchange Commission (SEC),
including but not limited to our Quarterly Report on Form 10-Q for
the quarter ended June 30, 2018,
which was filed with the SEC on August 7,
2018. These forward-looking statements represent Arena's
judgment as of the time of this release. Arena disclaims any intent
or obligation to update these forward-looking statements, other
than as may be required under applicable law.
Corporate
Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, M.D.
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original content with
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-at-upcoming-investor-conferences-300704422.html
SOURCE Arena Pharmaceuticals, Inc.